Literature DB >> 6965294

Priming and suppression of the intestinal immune response to cholera toxoid/toxin by parenteral toxoid in rats.

N F Pierce, F T Koster.   

Abstract

Parenteral immunization of rats with cholera toxoid had both priming and suppressive effects upon the antitoxin response in jejunal lamina propria to locally applied toxoid/toxin. Priming was detected when parenteral toxoid was given i.p. but not i.v. or s.c., was enhanced by Freund's adjuvant, and appeared to reflect enhanced encounter of i.p. antigen with IgA-committed lymphocytes in extra-intestinal mucosa-associated lymphoid tissue. In contrast, suppression followed parenteral toxoid given i.p., i.v., or s.c.; suppression was antigen specific and lasted at least 16 weeks. Parenteral toxoid suppressed both primary and secondary types of mucosal antitoxin responses, ultimately preventing the generation of antitoxin-containing immunoblasts from Peyer's patches. Since suppression followed parenteral immunization by routes that did not provoke mucosal priming, it was, at least in those instances, not simply a regulatory consequence of mucosal priming. These results support the notion that priming and suppression of a specific mucosal immune response are independent effects of parenteral immunization that are probably determined by the distribution of antigen to mucosa-associated and systemic lymphoid tissue, respectively.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6965294

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines.

Authors:  A B Hartman; L L Van de Verg; H H Collins; D B Tang; N O Bendiuk; D N Taylor; C J Powell
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

2.  Immunization against rabies with plant-derived antigen.

Authors:  A Modelska; B Dietzschold; N Sleysh; Z F Fu; K Steplewski; D C Hooper; H Koprowski; V Yusibov
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

3.  Quantification of antigen-specific antibody-secreting cells in the small intestine and other lymphoid organs of mice after oral booster immunization.

Authors:  P J Van der Heijden; A T Bianchi; B A Bokhout; M Dol; J W Scholten; W Stok
Journal:  Immunology       Date:  1989-03       Impact factor: 7.397

4.  Establishment of an animal model of ovalbumin sensitised mouse to study protein induced enteropathy.

Authors:  C Malo; C L Morin
Journal:  Gut       Date:  1986-11       Impact factor: 23.059

Review 5.  The common mucosal immune system and current strategies for induction of immune responses in external secretions.

Authors:  J Mestecky
Journal:  J Clin Immunol       Date:  1987-07       Impact factor: 8.317

6.  Local and systemic antibody responses and immunological memory in humans after immunization with cholera B subunit by different routes.

Authors:  A M Svennerholm; L Gothefors; D A Sack; P K Bardhan; J Holmgren
Journal:  Bull World Health Organ       Date:  1984       Impact factor: 9.408

7.  Immunological cross-reactivity of enterotoxins of Aeromonas hydrophila and cholera toxin.

Authors:  C James; M Dibley; V Burke; J Robinson; M Gracey
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

8.  The influence of different immunization pathways on the immunological response in the oral mucosa.

Authors:  D Muller; E J Ruitenberg; A Elgersma
Journal:  Br J Exp Pathol       Date:  1983-08

9.  Oral immunization of dogs with purified cholera toxin, crude cholera toxin, or B subunit: evidence for synergistic protection by antitoxic and antibacterial mechanisms.

Authors:  N F Pierce; W C Cray; J B Sacci
Journal:  Infect Immun       Date:  1982-08       Impact factor: 3.441

10.  Hamster challenge potency assay for evaluation of Mycoplasma pneumoniae vaccines.

Authors:  M F Barile; D K Chandler; H Yoshida; M W Grabowski; S Razin
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.